{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T04:09:07Z","timestamp":1794283747300,"version":"4.9.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T00:00:00Z","timestamp":1651449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T00:00:00Z","timestamp":1651449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Stem cell transplantation (SCT) has paved the way for treatment of autoimmune diseases. SCT has been investigated in type 1 diabetes mellitus (T1DM) as an autoimmune-based disorder, but previous studies have not presented a comprehensive view of its effect on treatment of T1DM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methodology<\/jats:title><jats:p>After registration of the present systematic review and meta-analysis in the PROSPERO, a search was done according to the Cochrane guidelines for evaluation of clinical trials to find eligible clinical trials that investigated the effect of SCT on T1DM (based on ADA\u00ae diagnostic criteria) from PubMed, Web of science, Scopus, etc, as well as registries of clinical trials from January 1, 2000, to September 31, 2019. A search strategy was designed using MeSH and EM-tree terms. Primary outcome included the changes in the insulin total daily dose (TDD) (U\/kg) level, and secondary outcomes included the changes in the HbA1c, c-peptide, and adjusted HbA1c levels. The<jats:italic>Q<\/jats:italic>Cochrane test and<jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>statistic were performed to assess the heterogeneity and its severity in primary clinical trials. The Cochrane ROB was used to determine risk of bias, and Cochrane Handbook for Systematic Reviews of Interventions was used in the full text papers. The meta-analysis was accomplished in the STATA software, and the results were shown on their forest plots. Confounders were evaluated by the meta-regression test.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 9452 studies were electronically screened, and 35 papers were included for data extraction. The results of this review study showed that 173 (26.5%) diabetic patients experienced insulin-free period (from 1 to 80\u2009months), and 445 (68%) showed reduction in TDD of insulin after the SCT. Combination of hematopoietic stem cell (HSC) with mesenchymal stem cell (MSC) transplantation were significantly associated with improvement of the TDD (SMD: \u2212\u20090.586, 95% CI: \u2212\u20091.204\/\u2212\u20090.509,<jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>: 0%), HbA1c (SMD: \u2212\u20090.736, 95% CI: \u2212\u20091.107\/\u2212\u20090.365,<jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>: 0%), adjusted HbA1c (SMD: \u2212\u20092.041, 95% CI: \u2212\u20092.648\/\u2212\u20091.434,<jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>: 38.4%), and c-peptide (SMD: 1.917, 95% CI: 0.192\/3.641,<jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>: 92.5%) on month 3 of follow-up, while its association had a growing trend from 3 to 12\u2009months after the transplantation. Considering severe adverse events, HSC transplantation accompanied with conditioning could not be suggested as a safe treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Most of the clinical trials of SCT in T1DM were single arm. Although meta-analysis illustrated the SCT is associated with T1DM improvement, well-designed randomized clinical trials are needed to clarify its efficacy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Recommendation<\/jats:title><jats:p>Based on the results of this meta-analysis, the MSC and its combination with HSC could be considered as \u201cSafe Cell\u201d for SCT in T1DM. Furthermore, to evaluate the SCT efficacy, calculation of insulin TDD (U\/kg\/day), AUC of c-peptide, and adjusted HbA1c are highly recommended.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13643-022-01950-3","type":"journal-article","created":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T09:02:37Z","timestamp":1651482157000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Investigating the safety and efficacy of hematopoietic and mesenchymal stem cell transplantation for treatment of T1DM: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1826-6574","authenticated-orcid":false,"given":"Sedigheh","family":"Madani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdiyeh","family":"Amanzadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid Reza","family":"Aghayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aria","family":"Setudeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negar","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahtab","family":"Rouhifard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bagher","family":"Larijani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,2]]},"reference":[{"key":"1950_CR1","volume-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2017","unstructured":"International Diabetes Federation. IDF Diabetes Atlas. 8th ed. Brussels: International Diabetes Federation; 2017. http:\/\/www.diabetesatlas.orgbetesfederation","edition":"8"},{"issue":"7","key":"1950_CR2","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1007\/s00125-004-1431-6","volume":"47","author":"M Nordwall","year":"2004","unstructured":"Nordwall M, et al. Declining incidence of severe retinopathy and persisting decrease of nephropathy in an unselected population of type 1 diabetes\u2014the Link\u00f6ping Diabetes Complications Study. Diabetologia. 2004;47(7):1266\u201372.","journal-title":"Diabetologia"},{"issue":"5","key":"1950_CR3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/j.1399-5448.2006.00204.x","volume":"7","author":"T Skrivarhaug","year":"2006","unstructured":"Skrivarhaug T, et al. Low risk of overt nephropathy after 24\u2009yr of childhood-onset type 1 diabetes mellitus (T1DM) in Norway. Pediatr Diabetes. 2006;7(5):239\u201346.","journal-title":"Pediatr Diabetes"},{"key":"1950_CR4","first-page":"23","volume-title":"ISPAD Clinical Practice Consensus Guidelines 2018- stages of type 1 diabetes in children and adolescents","author":"JJ Couper","year":"2018","unstructured":"Couper JJ, et al. ISPAD Clinical Practice Consensus Guidelines 2018- stages of type 1 diabetes in children and adolescents; 2018. p. 23."},{"issue":"3","key":"1950_CR5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/sj.bmt.1704134","volume":"32","author":"W Kreisel","year":"2003","unstructured":"Kreisel W, et al. Complete remission of Crohn\u2019s disease after high-dose cyclophosphamide and autologous stem cell transplantation. Bone Marrow Transplant. 2003;32(3):337.","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"1950_CR6","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1517\/14712598.2011.602967","volume":"11","author":"PJ Mannon","year":"2011","unstructured":"Mannon PJ. Remestemcel-L: human mesenchymal stem cells as an emerging therapy for Crohn\u2019s disease. Expert Opin Biol Ther. 2011;11(9):1249\u201356.","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"1950_CR7","doi-asserted-by":"publisher","first-page":"S169","DOI":"10.1016\/j.bbmt.2009.12.057","volume":"16","author":"P Martin","year":"2010","unstructured":"Martin P, et al. Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease (SR-GVHD) involving the liver and gut: results of a randomized, placebo-controlled, multicenter phase III trial in GVHD. Biol Blood Marrow Transplant. 2010;16(2):S169\u201370.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"1950_CR8","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1186\/2193-1801-3-440","volume":"3","author":"AA Matar","year":"2014","unstructured":"Matar AA, Chong JJ. Stem cell therapy for cardiac dysfunction. Springerplus. 2014;3(1):440.","journal-title":"Springerplus"},{"issue":"7","key":"1950_CR9","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1089\/ten.2007.0047","volume":"13","author":"LT Lock","year":"2007","unstructured":"Lock LT, Tzanakakis ES. Stem\/progenitor cell sources of insulin-producing cells for the treatment of diabetes. Tissue Eng. 2007;13(7):1399\u2013412.","journal-title":"Tissue Eng"},{"key":"1950_CR10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fendo.2014.00086","volume":"5","author":"GC Davey","year":"2014","unstructured":"Davey GC, et al. Mesenchymal stem cell-based treatment for microvascular and secondary complications of diabetes mellitus. Front Endocrinol. 2014;5:86.","journal-title":"Front Endocrinol"},{"issue":"9","key":"1950_CR11","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.2337\/db14-0295","volume":"63","author":"F D\u2019Addio","year":"2014","unstructured":"D\u2019Addio F, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in new-onset type 1 diabetes: a multicenter analysis. Diabetes. 2014;63(9):3041\u20136.","journal-title":"Diabetes"},{"issue":"3","key":"1950_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2174\/157488812799859829","volume":"7","author":"M Mohamed","year":"2012","unstructured":"Mohamed M, Maha S. Mesenchymal stem cell-based therapy for the treatment of type 1 diabetes mellitus. Curr Stem Cell Res Ther. 2012;7(3):179\u201390.","journal-title":"Curr Stem Cell Res Ther"},{"issue":"9","key":"1950_CR13","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.3727\/096368913X665576","volume":"23","author":"A Bhansali","year":"2014","unstructured":"Bhansali A, et al. Efficacy and safety of autologous bone marrow-derived stem cell transplantation in patients with type 2 diabetes mellitus: a randomized placebo-controlled study. Cell Transplant. 2014;23(9):1075\u201385.","journal-title":"Cell Transplant"},{"key":"1950_CR14","first-page":"24","volume":"3","author":"B Cheng","year":"2016","unstructured":"Cheng B, Lu S-L, Fu X-B. Regenerative medicine in China: main progress in different fields. Mil Med Res. 2016;3:24.","journal-title":"Mil Med Res"},{"issue":"49","key":"1950_CR15","first-page":"9276","volume":"16","author":"YG Wang","year":"2013","unstructured":"Wang YG, Yu JS. Stem cells therapy for treatment of diabetic mellitus and complications. Chin J Tissue Eng Res. 2013;16(49):9276\u201382.","journal-title":"Chin J Tissue Eng Res"},{"issue":"4","key":"1950_CR16","doi-asserted-by":"publisher","first-page":"e0151938","DOI":"10.1371\/journal.pone.0151938","volume":"11","author":"A El-Badawy","year":"2016","unstructured":"El-Badawy A, El-Badri N. Clinical efficacy of stem cell therapy for diabetes mellitus: a meta-analysis. PLoS One. 2016;11(4):e0151938.","journal-title":"PLoS One"},{"issue":"6","key":"1950_CR17","first-page":"4479","volume":"16","author":"J Gan","year":"2018","unstructured":"Gan J, Wang Y, Zhou X. Stem cell transplantation for the treatment of patients with type 1 diabetes mellitus: a meta-analysis. Exp Ther Med. 2018;16(6):4479\u201392.","journal-title":"Exp Ther Med"},{"issue":"2","key":"1950_CR18","doi-asserted-by":"publisher","first-page":"195","DOI":"10.15283\/ijsc18076","volume":"12","author":"G Hwang","year":"2019","unstructured":"Hwang G, et al. Efficacies of stem cell therapies for functional improvement of the beta cell in patients with diabetes: a systematic review of controlled clinical trials. Int J Stem Cells. 2019;12(2):195\u2013205.","journal-title":"Int J Stem Cells"},{"issue":"1","key":"1950_CR19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.14336\/AD.2019.0421","volume":"11","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, et al. The clinical efficacy and safety of stem cell therapy for diabetes mellitus: a systematic review and meta-analysis. Aging Dis. 2020;11(1):141.","journal-title":"Aging Dis"},{"key":"1950_CR20","series-title":"Methodological Expectations of Cochrane Intervention Reviews (MECIR)","volume-title":"Toby Lasserson and David Tovey Methodological standards for the conduct of new Cochrane Intervention Reviews Version 2.1, 8","author":"RC Jackie Chandler","year":"2011","unstructured":"Jackie Chandler, R.C., Julian Higgins, Toby Lasserson and David Tovey Methodological standards for the conduct of new Cochrane Intervention Reviews Version 2.1, 8. Methodological Expectations of Cochrane Intervention Reviews (MECIR), 2011."},{"issue":"1","key":"1950_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13643-017-0662-9","volume":"7","author":"S Madani","year":"2018","unstructured":"Madani S, et al. Safety and efficacy of hematopoietic and mesanchymal stem cell therapy for treatment of T1DM: a systematic review and meta-analysis protocol. Syst Rev. 2018;7(1):23.","journal-title":"Syst Rev"},{"key":"1950_CR22","doi-asserted-by":"crossref","unstructured":"Moher D, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.\u00a0Syst Rev.\u00a02015;4(1):1-9.","DOI":"10.1186\/2046-4053-4-1"},{"issue":"1","key":"1950_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.5152\/tao.2019.4058","volume":"57","author":"AA Sel\u00e7uk","year":"2019","unstructured":"Sel\u00e7uk AA. A guide for systematic reviews: PRISMA. Turkish Arch Otorhinolaryngol. 2019;57(1):57\u20138.","journal-title":"Turkish Arch Otorhinolaryngol"},{"key":"1950_CR24","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"1950_CR25","volume-title":"Evaluation and treatment of cryptorchidism-Appendix E, quality of the literature-Cochrane risk of bias tool for randomized controlled trials","author":"DF Penson","year":"2012","unstructured":"Penson DF, Krishnaswami S, Jules A, et al. Evaluation and treatment of cryptorchidism-Appendix E, quality of the literature-Cochrane risk of bias tool for randomized controlled trials. Rockville: Agency for Healthcare Research and Quality (US); 2012."},{"key":"1950_CR26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/9780470712184","volume-title":"Cochrane handbook for systematic reviews of interventions. Wiley Online Library","author":"JP Higgins","year":"2008","unstructured":"Higgins JP, G.S. Cochrane handbook for systematic reviews of interventions. Wiley Online Library; 2008. p. 5."},{"issue":"2","key":"1950_CR27","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2337\/db14-0656","volume":"64","author":"PO Carlsson","year":"2015","unstructured":"Carlsson PO, et al. Preserved beta-cell function in type 1 diabetes by mesenchymal stromal cells. Diabetes. 2015;64(2):587\u201392.","journal-title":"Diabetes"},{"key":"1950_CR28","first-page":"55","volume":"44","author":"EN Esfahani","year":"2015","unstructured":"Esfahani EN, et al. Administration of autologous mesenchymal stem cell transplantation for treatment of type 1 diabetes mellitus. Iran J Public Health. 2015;44:55\u201368.","journal-title":"Iran J Public Health"},{"issue":"3","key":"1950_CR29","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1507\/endocrj.EJ12-0343","volume":"60","author":"JX Hu","year":"2013","unstructured":"Hu JX, et al. Long term effects of the implantation of Wharton\u2019s jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus. Endocr J. 2013;60(3):347\u201357.","journal-title":"Endocr J"},{"issue":"4","key":"1950_CR30","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1177\/0300060513487640","volume":"41","author":"Y Liu","year":"2013","unstructured":"Liu Y, et al. Amniotic stem cell transplantation therapy for type 1 diabetes: a case report. J Int Med Res. 2013;41(4):1370\u20137.","journal-title":"J Int Med Res"},{"key":"1950_CR31","doi-asserted-by":"publisher","first-page":"852","DOI":"10.12659\/MSM.889525","volume":"19","author":"A Mesples","year":"2013","unstructured":"Mesples A, et al. Early immunotherapy using autologous adult stem cells reversed the effect of anti-pancreatic islets in recently diagnosed type 1 diabetes mellitus: preliminary results. Med Sci Monit. 2013;19:852\u20137.","journal-title":"Med Sci Monit"},{"issue":"Suppl 1","key":"1950_CR32","doi-asserted-by":"publisher","first-page":"236","DOI":"10.6002\/ect.MESOT2018.P100","volume":"17","author":"O Ulyanova","year":"2019","unstructured":"Ulyanova O, et al. Autologous mesenchymal stem cell transplant in patients with type 1 diabetes mellitus. Exp Clin Transplant. 2019;17(Suppl 1):236\u20138.","journal-title":"Exp Clin Transplant"},{"issue":"5","key":"1950_CR33","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1210\/jc.2015-2776","volume":"101","author":"OG Cantu-Rodriguez","year":"2016","unstructured":"Cantu-Rodriguez OG, et al. Long-term insulin independence in type 1 diabetes mellitus using a simplified autologous stem cell transplant. J Clin Endocrinol Metab. 2016;101(5):2141\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"1950_CR34","first-page":"27","volume":"44","author":"M Ghodsi","year":"2015","unstructured":"Ghodsi M, et al. Insulin independence after fetal liver-derived cell suspension allotransplantation in patients with type 1 diabetes: a pilot study. Iran J Public Health. 2015;44:27\u201335.","journal-title":"Iran J Public Health"},{"issue":"15","key":"1950_CR35","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1001\/jama.2009.470","volume":"301","author":"CE Couri","year":"2009","unstructured":"Couri CE, et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2009;301(15):1573\u20139.","journal-title":"JAMA"},{"issue":"8","key":"1950_CR36","first-page":"541","volume":"50","author":"M Ghodsi","year":"2012","unstructured":"Ghodsi M, et al. The effect of fetal liver-derived cell suspension allotransplantation on patients with diabetes: first year of follow-up. Acta Med Iran. 2012;50(8):541\u20136.","journal-title":"Acta Med Iran"},{"issue":"7","key":"1950_CR37","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.2337\/dc11-2161","volume":"35","author":"W Gu","year":"2012","unstructured":"Gu W, et al. Diabetic ketoacidosis at diagnosis influences complete remission after treatment with hematopoietic stem cell transplantation in adolescents with type 1 diabetes. Diabetes Care. 2012;35(7):1413\u20139.","journal-title":"Diabetes Care"},{"issue":"14","key":"1950_CR38","first-page":"2618","volume":"127","author":"Y Gu","year":"2014","unstructured":"Gu Y, et al. Autologous hematopoietic stem cell transplantation and conventional insulin therapy in the treatment of children with newly diagnosed type 1 diabetes: long term follow-up. Chin Med J. 2014;127(14):2618\u201322.","journal-title":"Chin Med J"},{"key":"1950_CR39","doi-asserted-by":"crossref","unstructured":"Gu B, et al. Clinical benefits of autologous haematopoietic stem cell transplantation in type 1 diabetes patients. Diabetes Metab. 2017;44(4):341-345.","DOI":"10.1016\/j.diabet.2017.12.006"},{"key":"1950_CR40","doi-asserted-by":"crossref","unstructured":"Haller MJ, et al. Autologous umbilical cord blood transfusion in young children with type 1 diabetes fails to preserve C-peptide. Diabetes Care. 2011;34(12):DC_111406.","DOI":"10.2337\/dc11-1406"},{"issue":"3","key":"1950_CR41","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/bmt.2011.113","volume":"47","author":"AM Leal","year":"2012","unstructured":"Leal AM, et al. Testicular function in patients with type 1 diabetes treated with high-dose CY and autologous hematopoietic SCT. Bone Marrow Transplant. 2012;47(3):467\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"1950_CR42","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1210\/jc.2011-2188","volume":"97","author":"L Li","year":"2012","unstructured":"Li L, et al. Autologous hematopoietic stem cell transplantation modulates immunocompetent cells and improves beta-cell function in Chinese patients with new onset of type 1 diabetes. J Clin Endocrinol Metab. 2012;97(5):1729\u201336.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"1950_CR43","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/S1575-0922(07)71497-3","volume":"54","author":"AD Mesples","year":"2007","unstructured":"Mesples AD, Preti\u00f1e B, Bellomo R. Tratamiento de la diabetes mellitus tipo 1 con implante pancre\u00e1tico de c\u00e9lulas madre adultas aut\u00f3logas. Endocrinol Nutr. 2007;54(10):512\u20138.","journal-title":"Endocrinol Nutr"},{"issue":"4","key":"1950_CR44","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/j.1753-0407.2012.00214.x","volume":"4","author":"S Shen","year":"2012","unstructured":"Shen S, et al. Remission induced by autologous hematopoietic stem cell transplantation in one newly diagnosed type 1 diabetes patient with diabetic ketoacidosis: a case report. J Diabetes. 2012;4(4):359\u201361.","journal-title":"J Diabetes"},{"issue":"6","key":"1950_CR45","doi-asserted-by":"crossref","first-page":"422","DOI":"10.20452\/pamw.725","volume":"119","author":"E Snarski","year":"2009","unstructured":"Snarski E, et al. Alleviation of exogenous insulin requirement in type 1 diabetes mellitus after immunoablation and transplantation of autologous hematopoietic stem cells. Pol Arch Med Wewn. 2009;119(6):422\u20136.","journal-title":"Pol Arch Med Wewn"},{"issue":"4","key":"1950_CR46","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/bmt.2010.147","volume":"46","author":"E Snarski","year":"2011","unstructured":"Snarski E, et al. Independence of exogenous insulin following immunoablation and stem cell reconstitution in newly diagnosed diabetes type I. Bone Marrow Transplant. 2011;46(4):562\u20136.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"1950_CR47","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/bmt.2015.294","volume":"51","author":"E Snarski","year":"2016","unstructured":"Snarski E, et al. Immunoablation and autologous hematopoietic stem cell transplantation in the treatment of new-onset type 1 diabetes mellitus: long-term observations. Bone Marrow Transplant. 2016;51(3):398\u2013402.","journal-title":"Bone Marrow Transplant"},{"key":"1950_CR48","first-page":"36","volume":"44","author":"A Tootee","year":"2015","unstructured":"Tootee A, et al. Application of allotransplantation of fetal liver-derived stem-cells for treatment of type 1 diabetes: a single-arm, phase 3 clinical trial. Iran J Public Health. 2015;44:36\u201341.","journal-title":"Iran J Public Health"},{"issue":"14","key":"1950_CR49","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1001\/jama.297.14.1568","volume":"297","author":"JC Voltarelli","year":"2007","unstructured":"Voltarelli JC, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2007;297(14):1568\u201376.","journal-title":"JAMA"},{"issue":"5","key":"1950_CR50","doi-asserted-by":"publisher","first-page":"651","DOI":"10.5966\/sctm.2015-0144","volume":"5","author":"H Xiang","year":"2016","unstructured":"Xiang H, et al. Residual beta-cell function predicts clinical response after autologous hematopoietic stem cell transplantation. Stem Cells Transl Med. 2016;5(5):651\u20137.","journal-title":"Stem Cells Transl Med"},{"key":"1950_CR51","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13287-017-0542-1","volume":"8","author":"L Ye","year":"2017","unstructured":"Ye L, et al. Immune response after autologous hematopoietic stem cell transplantation in type 1 diabetes mellitus. Stem Cell Res Ther. 2017;8:90.","journal-title":"Stem Cell Res Ther"},{"issue":"2","key":"1950_CR52","doi-asserted-by":"publisher","first-page":"e31887","DOI":"10.1371\/journal.pone.0031887","volume":"7","author":"X Zhang","year":"2012","unstructured":"Zhang X, et al. Acute response of peripheral blood cell to autologous hematopoietic stem cell transplantation in type 1 diabetic patient. PLoS One. 2012;7(2):e31887.","journal-title":"PLoS One"},{"issue":"1","key":"1950_CR53","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2337\/dc15-0171","volume":"39","author":"JQ Cai","year":"2016","unstructured":"Cai JQ, et al. Umbilical cord mesenchymal stromal cell with autologous bone marrow cell transplantation in established type 1 diabetes: a pilot randomized controlled open-label clinical study to assess safety and impact on insulin secretion. Diabetes Care. 2016;39(1):149\u201357.","journal-title":"Diabetes Care"},{"key":"1950_CR54","doi-asserted-by":"crossref","first-page":"bcr2013009901","DOI":"10.1136\/bcr-2013-009901","volume":"2013","author":"SD Dave","year":"2013","unstructured":"Dave SD, Vanikar AV, Trivedi HL. Co-infusion of adipose tissue derived mesenchymal stem cell-differentiated insulin-making cells and haematopoietic cells with renal transplantation: a novel therapy for type 1 diabetes mellitus with end-stage renal disease. BMJ Case Rep. 2013;2013:bcr2013009901.","journal-title":"BMJ Case Rep"},{"key":"1950_CR55","doi-asserted-by":"publisher","first-page":"bcr2013201238","DOI":"10.1136\/bcr-2013-201238","volume":"2014","author":"SD Dave","year":"2014","unstructured":"Dave SD, et al. Combined therapy of insulin-producing cells and haematopoietic stem cells offers better diabetic control than only haematopoietic stem cells\u2019 infusion for patients with insulin-dependent diabetes. BMJ Case Rep. 2014;2014:bcr2013201238.","journal-title":"BMJ Case Rep"},{"issue":"1","key":"1950_CR56","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10238-013-0266-1","volume":"15","author":"S Dave","year":"2013","unstructured":"Dave S, et al. Novel therapy for insulin-dependent diabetes mellitus: infusion of in vitro-generated insulin-secreting cells. Clin Exp Med. 2013;15(1):41\u20135.","journal-title":"Clin Exp Med"},{"issue":"7","key":"1950_CR57","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jcyt.2015.03.608","volume":"17","author":"UG Thakkar","year":"2015","unstructured":"Thakkar UG, et al. Insulin-secreting adipose-derived mesenchymal stromal cells with bone marrow-derived hematopoietic stem cells from autologous and allogenic sources for type 1 diabetes mellitus. Cytotherapy. 2015;17(7):940\u20137.","journal-title":"Cytotherapy"},{"issue":"4","key":"1950_CR58","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.transproceed.2008.03.113","volume":"40","author":"HL Trivedi","year":"2008","unstructured":"Trivedi HL, et al. Human adipose tissue-derived mesenchymal stem cells combined with hematopoietic stem cell transplantation synthesize insulin. Transplant Proc. 2008;40(4):1135\u20139.","journal-title":"Transplant Proc"},{"key":"1950_CR59","doi-asserted-by":"publisher","first-page":"bcr0720114436","DOI":"10.1136\/bcr.07.2011.4436","volume":"2011","author":"HL Trivedi","year":"2011","unstructured":"Trivedi HL, et al. Treatment of polyglandular autoimmune syndrome type 3 using co-transplantation of insulin-secreting mesenchymal stem cells and haematopoietic stem cells. BMJ Case Rep. 2011;2011:bcr0720114436.","journal-title":"BMJ Case Rep"},{"key":"1950_CR60","doi-asserted-by":"publisher","first-page":"582382","DOI":"10.4061\/2010\/582382","volume":"2010","author":"AV Vanikar","year":"2010","unstructured":"Vanikar AV, et al. Cotransplantation of adipose tissue-derived insulin-secreting mesenchymal stem cells and hematopoietic stem cells: a novel therapy for insulin-dependent diabetes mellitus. Stem Cells Int. 2010;2010:582382.","journal-title":"Stem Cells Int"},{"key":"1950_CR61","volume-title":"Common Terminology Criteria for Adverse Events version 5.0","author":"SERVICES, U.S.D.O.H.A.H","year":"2017","unstructured":"SERVICES, U.S.D.O.H.A.H. Common Terminology Criteria for Adverse Events version 5.0: U.S. Department of Health and Human Services; 2017."},{"key":"1950_CR62","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1196\/annals.1447.054","volume":"1150","author":"JS Skyler","year":"2008","unstructured":"Skyler JS, et al. Type 1 Diabetes TrialNet\u2013an international collaborative clinical trials network. Ann N Y Acad Sci. 2008;1150:14.","journal-title":"Ann N Y Acad Sci"},{"issue":"11","key":"1950_CR63","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1007\/s00125-017-4384-2","volume":"60","author":"M Battaglia","year":"2017","unstructured":"Battaglia M, et al. Understanding and preventing type 1 diabetes through the unique working model of TrialNet. Diabetologia. 2017;60(11):2139\u201347.","journal-title":"Diabetologia"},{"key":"1950_CR64","volume-title":"Pediatric endocrinology E-Book: expert consult-online and print","author":"MA Sperling","year":"2014","unstructured":"Sperling MA. Pediatric endocrinology E-Book: expert consult-online and print: Elsevier Health Sciences; 2014."},{"issue":"2","key":"1950_CR65","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2337\/diacare.28.2.343","volume":"28","author":"EA Ryan","year":"2005","unstructured":"Ryan EA, et al. \u03b2-Score: an assessment of \u03b2-cell function after islet transplantation. Diabetes Care. 2005;28(2):343\u20137.","journal-title":"Diabetes Care"},{"issue":"7","key":"1950_CR66","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/pedi.12208","volume":"15","author":"MLC Max Andersen","year":"2014","unstructured":"Max Andersen MLC, et al. Partial remission definition: validation based on the insulin dose-adjusted HbA1c (IDAA1C) in 129 Danish children with new-onset type 1 diabetes. Pediatr Diabetes. 2014;15(7):469\u201376.","journal-title":"Pediatr Diabetes"},{"issue":"5","key":"1950_CR67","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/dme.12097","volume":"30","author":"O Neylon","year":"2013","unstructured":"Neylon O, et al. Insulin-dose-adjusted HbA1c-defined partial remission phase in a paediatric population\u2014when is the honeymoon over? Diabet Med. 2013;30(5):627\u20138.","journal-title":"Diabet Med"},{"key":"1950_CR68","doi-asserted-by":"publisher","first-page":"824","DOI":"10.3389\/fendo.2019.00824","volume":"10","author":"R Tang","year":"2019","unstructured":"Tang R. The remission phase in type 1 diabetes: role of hyperglycemia rectification in immune modulation. Front Endocrinol. 2019;10:824.","journal-title":"Front Endocrinol"},{"key":"1950_CR69","doi-asserted-by":"crossref","unstructured":"Hashemi SM, et al. Investigating the route of administration and efficacy of adipose tissue-derived mesenchymal stem cells and conditioned medium in type 1 diabetic mice. Inflammopharmacology. 2019;28(2):1\u201317.","DOI":"10.1007\/s10787-019-00661-x"},{"issue":"1","key":"1950_CR70","doi-asserted-by":"publisher","first-page":"260","DOI":"10.15419\/psc.v6i1.403","volume":"6","author":"A Kazmi","year":"2019","unstructured":"Kazmi A, et al. Mesenchymal stem cells transplantation reduces diabetic nephropathy. Progress Stem Cell. 2019;6(1):260\u20138.","journal-title":"Progress Stem Cell"},{"issue":"2","key":"1950_CR71","doi-asserted-by":"publisher","first-page":"S252","DOI":"10.1016\/j.bbmt.2011.12.141","volume":"18","author":"OG Cantu-Rodriguez","year":"2012","unstructured":"Cantu-Rodriguez OG, et al. Outpatient stem cell transplantation using a reduced-intensity conditioning in type i diabetes mellitus. Biol Blood Marrow Transplant. 2012;18(2):S252.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"21","key":"1950_CR72","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1182\/blood.V124.21.1191.1191","volume":"124","author":"OG Cantu-Rodriguez","year":"2014","unstructured":"Cantu-Rodriguez OG, et al. Autologus hematopoietic stem cell transplant in type 1 diabetes mellitus in a nonmyeloablative and outpatient setting. Blood. 2014;124(21):1191.","journal-title":"Blood"},{"issue":"1","key":"1950_CR73","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jocit.2014.12.001","volume":"2","author":"Q Zhao","year":"2016","unstructured":"Zhao Q, Ren H, Han Z. Mesenchymal stem cells: immunomodulatory capability and clinical potential in immune diseases. J Cell Immunother. 2016;2(1):3\u201320.","journal-title":"J Cell Immunother"},{"issue":"6 Pt 2","key":"1950_CR74","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/j.lpm.2016.05.002","volume":"45","author":"A Tyndall","year":"2016","unstructured":"Tyndall A, van Laar JM. Stem cell transplantation and mesenchymal cells to treat autoimmune diseases. Presse Med. 2016;45(6 Pt 2):e159\u201369.","journal-title":"Presse Med"},{"key":"1950_CR75","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.cytogfr.2019.05.006","volume":"47","author":"A\u00c9S Carvalho","year":"2019","unstructured":"Carvalho A\u00c9S, et al. Mesenchymal stem cells immunomodulation: the road to IFN-\u03b3 licensing and the path ahead. Cytokine Growth Factor Rev. 2019;47:32\u201342.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"10","key":"1950_CR76","doi-asserted-by":"publisher","first-page":"e47559","DOI":"10.1371\/journal.pone.0047559","volume":"7","author":"MM Lalu","year":"2012","unstructured":"Lalu MM, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One. 2012;7(10):e47559.","journal-title":"PLoS One"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-022-01950-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-022-01950-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-022-01950-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T14:16:32Z","timestamp":1727100992000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-022-01950-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,2]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1950"],"URL":"https:\/\/doi.org\/10.1186\/s13643-022-01950-3","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,2]]},"assertion":[{"value":"19 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical approval was sought because this review study did not include the human participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We have no restriction for publishing this systematic review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"82"}}